At December 31, 2022, Viking held cash, cash equivalents and short-term investments of $155M, compared to $202M as of December 31, 2021."Our progress throughout 2022 has positioned Viking for an exciting year in 2023, and we expect to report data from all three of our active clinical programs this year," stated Brian Lian, CEO. "With respect to our lead compound, VK2809 for the treatment of NASH and fibrosis, we have completed enrollment in our Phase 2b VOYAGE trial, and we expect to report initial data, including the trial’s primary endpoint, in the second quarter of 2023. The Phase 1 study evaluating our dual-agonist compound, VK2735, continues to progress and we expect to report the initial data from this study later this quarter. Finally, our Phase 1b trial evaluating VK0214 in X-ALD patients continues to enroll and we expect to report data from this trial later this year. Importantly, we are starting the year with a strong cash position of approximately $155M, providing an operating runway that extends beyond the key milestones for our clinical programs."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Viking Therapeutics options imply 11.2% move in share price post-earnings
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
- Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809
